Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
It has planned an investment of over Rs 80 crore in the next five years
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The company received one observation in the Form-483
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Subscribe To Our Newsletter & Stay Updated
